ID | 1119 |
Name of the vaccine | TYPHIBEV |
Microbe | Bacteria |
Disease name | Typhoid |
Name of bacteria | Salmonella typhi |
Type of vaccine | Conjugate |
Nucleic acid content | DNA |
Age | 6 months to 45 years |
Description of the vaccine | Formulated with Vi polysaccharide conjugated to a carrier protein (CRM197). |
Name of the manufacturer | Biological E |
Name of the manufacturing country | India |
Year of manufacture | 2020 |
Clinical Phase status | Approved |
Bacterial strain | Gram negative bacteria. |
Efficacy | 79-85% efficacy against typhoid fever. |
Vaccine formulation | NA |
Dosage | Single dose and a booster dose may be given after 3 years. |
Mechanism of action | Through conjugation, TCVs are able to stimulate parts of the immune system and give long lasting immunity. |
Route of administration | Intramuscular |
Indications | Long term protection against typhoid fever. |
Export | Allowed to be purchased by United Nations agencies. |
Approval | WHO pre-qualified |
Adjuvant | NA |
Repurposing | NA |
Side effects of vaccine | NA |
Post vaccination | NA |
Dose type | Single dose |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://www.coalitionagainsttyphoid.org/the-issues/typhoid-vaccines/ |
Other name | NA |
Additional Links | https://www.coalitionagainsttyphoid.org/wp-content/uploads/2021/06/TYPHIBEV-QA_May-2021.pdf
|